These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 16888811

  • 1. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.
    Moneo V, Serelde BG, Fominaya J, Leal JF, Blanco-Aparicio C, Romero L, Sánchez-Beato M, Cigudosa JC, Tercero JC, Piris MA, Jimeno J, Carnero A.
    J Cell Biochem; 2007 Feb 01; 100(2):339-48. PubMed ID: 16888811
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines.
    Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, Mankin H, Hornicek FJ.
    PLoS One; 2009 Sep 09; 4(9):e6967. PubMed ID: 19742314
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
    Amaral AT, Garofalo C, Frapolli R, Manara MC, Mancarella C, Uboldi S, Di Giandomenico S, Ordóñez JL, Sevillano V, Malaguarnera R, Picci P, Hassan AB, De Alava E, D'Incalci M, Scotlandi K.
    Clin Cancer Res; 2015 Mar 15; 21(6):1373-82. PubMed ID: 25609059
    [Abstract] [Full Text] [Related]

  • 12. Unique features of trabectedin mechanism of action.
    Larsen AK, Galmarini CM, D'Incalci M.
    Cancer Chemother Pharmacol; 2016 Apr 15; 77(4):663-71. PubMed ID: 26666647
    [Abstract] [Full Text] [Related]

  • 13. In vitro radiosensitisation by trabectedin in human cancer cell lines.
    Romero J, Zapata I, Córdoba S, Jimeno JM, López-Martín JA, Tercero JC, De La Torre A, Vargas JA, Molerón R, Sánchez-Prieto R.
    Eur J Cancer; 2008 Aug 15; 44(12):1726-33. PubMed ID: 18501589
    [Abstract] [Full Text] [Related]

  • 14. Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma.
    Nakai T, Imura Y, Tamiya H, Yamada S, Nakai S, Yasuda N, Kaneko K, Outani H, Takenaka S, Hamada K, Myoui A, Araki N, Ueda T, Itoh K, Yoshikawa H, Naka N.
    Cancer Med; 2017 Sep 15; 6(9):2121-2130. PubMed ID: 28745431
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.
    Cuevas C, Francesch A.
    Nat Prod Rep; 2009 Mar 15; 26(3):322-37. PubMed ID: 19240944
    [Abstract] [Full Text] [Related]

  • 20. Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models.
    Peraldo-Neia C, Cavalloni G, Soster M, Gammaitoni L, Marchiò S, Sassi F, Trusolino L, Bertotti A, Medico E, Capussotti L, Aglietta M, Leone F.
    BMC Cancer; 2014 Dec 05; 14():918. PubMed ID: 25479910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.